Geldanamycin derivatives and antitumor drug |
| OF THE PREFERRED EMBODIMENTS The Geldanamycin derivatives having the formula (I) can be produced ... |
|
Method and compositions for inhibiting protein kinases |
| We claim: 1. A method for inhibiting a protein kinase, which comprises: contacting a composition ... |
|
Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| OF THE INVENTION The present invention relates to the use of FVII or FVIIa or another TF agonist ... |
|
Method for providing enteric coating on solid dosage forms and aqueous compositions therefor |
| OF THE PREFERRED EMBODIMENTS Extensive investigations have been undertaken by the inventors with ... |
|
Method for preparing film coated pharmaceutical preparations and method for improving properties thereof |
| What is claimed is: 1. A method for providing white colored film coated pharmaceutical preparations,... |
|
Delayed, sustained-release pharmaceutical preparation |
| OF THE PREFERRED EMBODIMENTS The preferred delayed, sustained-release pharmaceutical preparation ... |
|
|
Heterocyclic oxophthalazinyl acetic acids
| Details |
Inventors: Larson, Eric R.; Mylari, Banavara L.;
Assignee: Pfizer Inc. (New York, NY)
Primary Examiner: Berch; Mark L.
Assistant Examiner:
Attorney, Agent or Firm: Richardson; Peter C., Ginsburg; Paul H., Holtrust; Gezina
A heterocyclic oxophthalazinyl acetic acid having aldose reductast inhibitory activity of the formula ##STR1## wherein X is oxygen or sulfur; Z is a covalent bond, O, S, NH or CH.sub.2 or CHR.sub.5 Z is vinyl; R.sub.1 is hydroxy, or a prodrug group; R.sub.2 is a heterocyclic group, R.sub.3 and R.sub.4 are hydrogen or the same or a different substituent, and R.sub.5 is hydrogen, methyl or trifluoromethyl. The pharmaceutically acceptable acid addition salts of the above compounds wherein R.sub.1 is di(C.sub.1 -C.sub.4)alkylamino or (C.sub.1 -C.sub.4)alkoxy substituted by N-morpholino or di(C.sub.1 -C.sub.4)alkylamino and the pharmaceutically active base addition salts of the above compounds wherein R.sub.1 is hydroxy are also aldose reductase inhibitors. |
|
DETAILED DESCRIPTION OF THE INVENTION The numbering system of the compounds of formula I is as shown: ##STR5## The term "(C. sub. 1 -C. sub. 4)alkyl" whenever used in the definitions of R. sub. 1 to R. sub. 4 denotes saturated monovalent straight or branched aliphatic hydrocarbon radicals having one to four carbon atoms, such as methyl, ethyl, propyl, butyl, t-butyl etc. The term "prodrug" denotes a group that is converted in vivo into the active compound of formula I wherein R. sub. 1 is hydroxy. Such groups are generally known in the art and include ester forming groups, to form an ester prodrug, such as benzyloxy, di(C. sub. 1 -C. sub. 4)alkylaminoethyloxy, acetoxymethyl, pivaloyloxymethyl, phthalidoyl, ethoxycarbonyloxyethyl, 5-methyl-2-oxo-1,3-dioxol-4-yl methyl, and (C. sub. 1 -C. sub. 4)alkoxy optionally substituted by N-morpholino and amide-forming groups such as di(C. sub. 1 -C. sub. 4)alkylamino. The heterocyclic 5-membered ring having one to three nitrogenatoms, one of which may be replaced by oxygen or sulfur includes imidazolyl, oxazolyl, thiazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, and triazolyl. The heterocyclic 6-membered ring having one to three nitrogen atoms, or one or two nitrogen atoms and one oxygen or sulfur includes triazinyl, pyrimidyl, pyridazinyl, oxazinyl and triazinyl. The heterocyclic ring may be condensed with benzo so that said ring is attached at two neighboring carbon atoms to form a phenyl group. Such benzoheterocyclic ring may be attached to Z either through the heterocyclic group or through the benzo group of the benzoheterocyclic ring. The preparation of those compounds wherein Z is attached to the benzo group is illustrated in Reaction Scheme B below. Specific examples wherein said heterocyclic ring is condensed with a benzo include benzoxazolyl, quinazolin-2-yl, 2-benzimidazolyl, quinazolin-4-yl and benzothiazolyl. The oxazole or thiazole condensed with a 6-membered aromatic group containing one or two nitrogen atoms include positional isomers such as oxazolo[4,5-b]pyridine-2-yl, thiazolo[4,5-b]pyridine-2-yl, oxazolo[4,5-c]pyridine-2-yl, thiazolo[4,5-c]pyridine-2-yl, oxazolo[5,4-b]pyridine-2-yl, thiazolo[5,4-b]pyridine-2-yl, oxazolo[5,4-c]pyridine-2-yl, and thiazolo[5,4-c]pyridine-2-yl
|
| Related patents |
|
|
Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
We claim: 1. The compounds of structural formula (I) ##STR5## wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl containining 1 to 6 carbon atoms, halogen, ...
|
|
|
Novel alpha-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
.alpha.-glucosidase inhibitors
What is claimed is: 1. 1-deoxy nojirimycin derivatives of the formula ##STR5## and the pharmaceutically acceptable acid addition salts thereof wherein n is zero, 1 or 2 ...
|
|
|
Oxetanones
OF THE INVENTION As used herein, the term "alkyl" denotes a straight or branched chain alkyl containing the number of carbon atoms designated. Examples of C.sub.1 -C....
|
|
|
Process for the preparation of .alpha.-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
We claim: 1. A compound of the Formula (I) ##STR7## wherein R is a C.sub.1 to C.sub.12 alkyl group substituted by C.sub.1 to C.sub.4 alkoxycarbonyl, a C.sub.3 to C.sub.9 ...
|
|
|
Inhibitor of absorption of digestion product of food and drink
OF THE INVENTION The following examples are to explain this invention in detail, not to limit its scope. EXAMPLE 1 Acqueous Enteric Material--Flocculant (a) Granules of ...
|
|
|
Hydantoin derivatives for treating complications of diabetes
OF PREFERRED EMBODIMENTS The invention will now be further explained with reference to Manufacturing Examples of the compounds and salts, Pharmacological Test Examples ...
|
|
|
Oral composition
OF THE INVENTION Although the present invention is described below with reference to examples, the present invention is not limited to the examples. Example 1 GS dry ...
|
|
|
Formulation for administration of steroid compounds
OF THE INVENTION By 5.beta. steroid is meant .alpha. ET, .beta. ET, and ED. In addition certain alkylated derivatives of these 5.beta. steroids are also included in ...
|
|
|